Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial

Feb 1, 2025Journal of diabetes investigation

Bodyweight loss linked to changes in fats, blood pressure, and blood sugar after tirzepatide treatment in Japanese people with type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

In a trial with 548 participants, showed significant improvements in metabolic parameters associated with bodyweight loss in individuals with type 2 diabetes.

Greater bodyweight loss correlated with improvements in metabolic parameters.
Weak but significant correlations were observed between bodyweight changes and triglycerides, high-density lipoprotein cholesterol, and systolic blood pressure.
Weight loss was linked to treatment differences between tirzepatide and dulaglutide 0.75 mg across various metabolic parameters.
Fasting serum glucose showed the lowest association with bodyweight loss among the metabolic improvements.

AI simplified

AIMS/INTRODUCTION: In the SURPASS J-mono trial, demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes. This post hoc analysis evaluated the potential relationships between weight loss and metabolic improvements in SURPASS J-mono.

MATERIALS AND METHODS: Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived. Mediation analyses were conducted to evaluate weight loss-associated and -unassociated effects of tirzepatide vs dulaglutide 0.75 mg.

RESULTS: This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137). Weight loss subgroups showed greater improvement in metabolic parameters with greater bodyweight loss. Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18-0.25), high-density lipoprotein cholesterol (r = -0.37 to -0.29), and systolic blood pressure (r = 0.19-0.41) were observed across treatment groups; in diastolic blood pressure in the tirzepatide 5-mg (r = 0.28), pooled tirzepatide (r = 0.20), and dulaglutide 0.75-mg (r = 0.23) groups; and in fasting serum glucose in the dulaglutide 0.75-mg (r = 0.18) and pooled tirzepatide (r = 0.13) groups. Weight loss was associated with treatment differences between tirzepatide and dulaglutide 0.75 mg to varying degrees across metabolic parameters, with improvements in fasting serum glucose having the lowest association with weight loss (36.6%-43.5%).

CONCLUSIONS: In this post hoc analysis, non-glycemic and glycemic parameter improvements appeared differentially associated with weight loss, suggesting both weight loss-associated and -unassociated effects of tirzepatide.

Key numbers

-0.37 to -0.29

Correlation with Improvement

Pearson correlation coefficients for across treatment groups.

36.6% to 43.5%

Improvement Contribution

Percentage of treatment difference attributed to weight loss.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief